Recent News
RRD International Retains The Chase Group
RRD International has retained The Chase Group to secure a Chief Development Officer to direct and manage the day-to-day activities of all RRD International product… Continue Reading →
Ipsen VP Neurology Franchise Secured
The Chase Group is proud to announce they recently completed a search for Vice President, Neurology Franchise for Ipsen US. Donald Pearl has been hired… Continue Reading →
Ipsen Biosciences Retains The Chase Group for Neuroendocrine Position
Ipsen Biosciences has retained The Chase Group to secure a Director of Molecular and Cellular Endocrinology who will lead the company’s research programs to devise… Continue Reading →
Durata Therapeutics and The Chase Group Partner Once Again
Durata Therapeutics has retained The Chase Group to secure two Executive Directors of Clinical and Medical Affairs to join their rapidly expanding clinical development team…. Continue Reading →
Ipsen US Retains The Chase Group
Ipsen US has retained The Chase Group to secure a VP Neurology Franchise to lead sales and marketing strategy development for commercializing products. Visionary and… Continue Reading →
ImClone Retains The Chase Group
The early phase oncology group at Imclone is seeking a physician/scientist with immunology experience to join their team. The Chase Group has been contracted to… Continue Reading →
The Chase Group Continues Successful Collaboration with AbbVie in Building Their Global Regulatory Group
The Chase Group announces the recruitment of Dr. Steve Engel and Dr. Monique Small as Global Regulatory Leads at AbbVie’s Chicago headquarters. Ken Allison remarked,… Continue Reading →
Chase and Lilly Diabetes Come Full Circle
The Chase Group has been retained to identify a diabetes/insulin expert to report into a physician who was recruited by Chase at Lilly over ten… Continue Reading →